Abstract
Osteoarthritis (OA) belongs to diseases with high comorbidity and is most frequently concurrent with hypertension and other cardiovascular diseases (coronary heart disease, atherosclerosis), obesity, and diabetes mellitus. The paper deals with the use of delayed-release symptomatic medications in the treatment of patients with OA and comorbidity. It reviews clinical trials of the efficacy and safety of diacerein in OA patients and its effect on comorbidity. The paper discusses the possibility of using diacerein as an alternative to traditional nonsteroidal anti-inflammatory drugs in patients with contraindications to the latter.
Highlights
Diacerein in the treatment of osteoarthritis in patients with comorbidity Sharapova E.P., Alekseeva L.I., Lila A.M
The paper deals with the use of delayed-release symptomatic medications in the treatment of patients with OA and comorbidity
The paper discusses the possibility of using diacerein as an alternative to traditional nonsteroidal anti-inflammatory drugs in patients with contraindications to the latter
Summary
Diacerein in the treatment of osteoarthritis in patients with comorbidity Sharapova E.P., Alekseeva L.I., Lila A.M. Оба препарата были эффективнее плацебо по влиянию на боль и функцию суставов, однако обезболивающий эффект теноксикама развивался быстрее, чем диацереина, действие которого было отмечено через 6 нед после начала лечения. Другое 8-недельное исследование эффективности диацереина показало его сравнимый с напроксеном обезболивающий эффект у больных ОА коленных и тазобедренных суставов, кроме того, действие диацереина сохранялось в течение 30 дней после прекращения лечения в отличие от такового напроксена [22].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
